A 28-year-old primigravida with Rh-negative blood group presents at 34 weeks of gestation with a history of vaginal bleeding following minor trauma. On examination, she is haemodynamically stable. The indirect Coombs test (ICT) is positive with an antibody titre of 1:16. Ultrasound shows a live singleton fetus with normal liquor volume. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient is an Rh-negative primigravida who is **already sensitised** — evidenced by a **positive Indirect Coombs Test (ICT)** with an antibody titre of 1:16. She presents at 34 weeks with vaginal bleeding following minor trauma, and the fetus is haemodynamically stable with normal liquor volume. ## Key Principle: Anti-D is NOT Indicated Once Sensitisation Has Occurred **High-Yield:** Anti-D immunoglobulin (Rh immunoglobulin) works by **preventing primary sensitisation** — it neutralises fetal Rh-positive red cells that enter the maternal circulation before the mother's immune system can mount a response. Once the mother has already formed anti-D antibodies (positive ICT), anti-D administration is **futile and not indicated**. The immune memory has already been established. This is a fundamental principle taught in all standard OBG texts (Dutta's Obstetrics, Ian Donald's Practical Obstetric Problems, Williams Obstetrics). ## Why Option D is Correct - The patient is **already sensitised** (positive ICT, titre 1:16) - Anti-D cannot reverse or suppress an established immune response - The fetus is **stable** at 34 weeks with no signs of hydrops or fetal distress - **Expectant management with close monitoring** is appropriate: - Serial antibody titres (every 2–4 weeks) - Middle cerebral artery (MCA) Doppler peak systolic velocity (PSV) to detect fetal anaemia non-invasively - Amniocentesis for ΔOD450 if MCA-PSV > 1.5 MoM ## Why the Other Options Are Wrong | Option | Reason Incorrect | |--------|-----------------| | A) Anti-D + amniocentesis | Anti-D is **contraindicated/futile** once sensitised; amniocentesis may be needed later but not as the immediate next step at 34 weeks with a stable fetus | | B) Immediate caesarean section | No indication — fetus is stable, no hydrops, 34 weeks is preterm; delivery decision is based on fetal condition | | C) Transfuse mother with Rh-positive blood | Absolutely contraindicated — would massively worsen sensitisation | ## Monitoring Strategy for Sensitised Rh-Negative Mothers | Parameter | Frequency/Threshold | |-----------|-------------------| | Antibody titre | Every 2–4 weeks; titre ≥ 1:16 is critical | | MCA-PSV Doppler | Weekly if titre ≥ 1:16; >1.5 MoM → fetal anaemia | | Amniocentesis ΔOD450 | If MCA-PSV elevated or Doppler unavailable | | Intrauterine transfusion | ΔOD450 in Liley Zone 2/3 or MCA-PSV >1.5 MoM | | Delivery timing | 37–38 weeks if mild; earlier if severe fetal compromise | **Clinical Pearl:** A titre of 1:16 is the **critical titre** — above this, the risk of significant haemolytic disease of the fetus/newborn (HDFN) is high, and intensive fetal surveillance (MCA Doppler) is mandatory. However, the **immediate next step** in a stable patient is expectant observation with surveillance — NOT anti-D (which is ineffective) and NOT immediate delivery. **Key Point (Williams Obstetrics, 26th ed.):** "Once a woman is sensitised, anti-D immunoglobulin serves no purpose. Management shifts to fetal surveillance to detect and treat haemolytic disease."